Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Accumulated Expenses: 2019-2025

Historic Accumulated Expenses for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $56.2 million.

  • BridgeBio Pharma's Accumulated Expenses rose 28.97% to $56.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.2 million, marking a year-over-year increase of 28.97%. This contributed to the annual value of $58.3 million for FY2024, which is 1.67% up from last year.
  • BridgeBio Pharma's Accumulated Expenses amounted to $56.2 million in Q3 2025, which was up 51.01% from $37.2 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Accumulated Expenses ranged from a high of $58.3 million in Q4 2024 and a low of $15.5 million during Q1 2022.
  • In the last 3 years, BridgeBio Pharma's Accumulated Expenses had a median value of $33.7 million in 2023 and averaged $39.0 million.
  • In the last 5 years, BridgeBio Pharma's Accumulated Expenses spiked by 177.84% in 2021 and then fell by 25.47% in 2022.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Accumulated Expenses stood at $37.0 million in 2021, then fell by 15.62% to $31.3 million in 2022, then spiked by 83.55% to $57.4 million in 2023, then climbed by 1.67% to $58.3 million in 2024, then grew by 28.97% to $56.2 million in 2025.
  • Its last three reported values are $56.2 million in Q3 2025, $37.2 million for Q2 2025, and $33.4 million during Q1 2025.